Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Has reproduction · 78
Purinergic adipocyte-macrophage crosstalk promotes degeneration of thermogenic brown adipose tissue.
PMID 41261284 · PMC12715258 · EMBO reports · 2025 · 8 claims · 8 setups
Imbalanced sympathetic/thermogenic activation (via UCP1 deficiency or pharmacological futile thermogenesis) causes BAT inflammation, fibrosis and degeneration
-
Full-text index only
Novel integrative genomics strategies to identify genes for complex traits.
PMID 16886998 · PMC2367618 · Animal genetics · 2006 · 8 claims · 7 setups
Forward genetics is restricted to genes harboring mutations, systematically missing network genes that causally influence disease without themselves being mutated.
-
Full-text index only
Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases.
PMID 19696895 · PMC2722371 · PLoS pathogens · 2009 · 7 claims · 8 setups
Hemozoin induces IL-1β maturation and secretion in an NLRP3-, ASC- and caspase-1-dependent, but NLRC4-independent, manner
-
Has reproduction · 83
FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice.
PMID 37226685 · PMC10331587 · EMBO molecular medicine · 2023 · 8 claims · 8 setups
ILEI protein, but not mRNA, is elevated in psoriatic skin and correlates with disease severity
-
Full-text index only
C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.
PMID 19997494 · PMC2778949 · PLoS pathogens · 2009 · 8 claims · 8 setups
The C-terminal helix of apoL1 is entirely responsible for its interaction with SRA
-
Full-text index only
Proteomic and genetic approaches identify Syk as an AML target.
PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups
EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism